Aspen Neuroscience, Inc.

ASPE chart

Aspen Neuroscience, Inc. news

• Form 4 Aspen Neuroscience: Faheem Hasnain (Director, Executive Chair) For: 5 November By Investing.com

  Investing.com India · Nov 9, 11:44 PM EST

• ARCH Venture Partners X Discloses 12.9% Stake in Aspen Neuroscience

  TradingView · Nov 9, 7:36 PM EST

• At $15 a share, ARCH funds buy into the Aspen Neuroscience (ASPE) IPO.

  Stock Titan · Nov 9, 7:29 PM EST

• A fully vested stock grant for Aspen Neuroscience (ASPE)'s chair awaits delivery in 2027.

  Stock Titan · Nov 9, 5:10 PM EST

• Five filers report the same Aspen Neuroscience (ASPE) stake.

  Stock Titan · Nov 9, 4:44 PM EST

• What Is Behind The Rise In Moderna Stock?

  trefis.com · Nov 7, 7:49 AM EST

• OrbiMed Reports 12.3% Stake in Aspen Neuroscience Following IPO Filing

  Kalkine Media · Nov 6, 6:46 PM EST

• OrbiMed Advisors Discloses Investment at Aspen Neuroscience, Inc. with 12.3% Stake

  TradingView · Nov 6, 6:46 PM EST

• After buying 1M IPO shares at $15, OrbiMed reports its stake in Aspen Neuroscience (ASPE).

  Stock Titan · Nov 6, 6:38 PM EST

• Aspen Neuroscience (ASPE) Stock Price, News & Analysis

  Stock Titan · Nov 6, 6:38 PM EST

• Gilead Sciences reports a passive stake in Aspen Neuroscience (ASPE).

  Stock Titan · Nov 6, 5:35 PM EST

• Aspen Neuroscience, Inc. (ASPE) insider ownership and holdings

  Yahoo Finance UK · Nov 6, 4:00 PM EST

Aspen Neuroscience, Inc. key financials

No XBRL financial data is available for this company yet.

Calendar-year figures as reported to the SEC in XBRL filings.

Recent SEC filings

• 8-K8-K2026-11-02
• S-1S-12026-10-09

About Aspen Neuroscience, Inc.

Ticker

ASPE (Nasdaq)

Industry

Pharmaceutical Preparations

Headquarters

San Diego, CA

Incorporated in

DE

Fiscal year end

December 31

SEC CIK

2124080

Frequently asked questions